781 related articles for article (PubMed ID: 29656663)
1. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
[TBL] [Abstract][Full Text] [Related]
2. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
[TBL] [Abstract][Full Text] [Related]
3. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM
Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
5. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.
Canuso CM; Ionescu DF; Li X; Qiu X; Lane R; Turkoz I; Nash AI; Lopena TJ; Fu DJ
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):516-524. PubMed ID: 34412104
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
[TBL] [Abstract][Full Text] [Related]
9. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
[TBL] [Abstract][Full Text] [Related]
11. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Hock RS; Feeney A; Iovieno N; Murrough JW; Mathew SJ; Iosifescu DV; Fava M; Jha MK; Papakostas GI
J Clin Psychiatry; 2022 Dec; 84(1):. PubMed ID: 36516320
[No Abstract] [Full Text] [Related]
12. Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression.
Surjan J; Grossi JD; Del Porto JA; Delfino RS; de Oliveira Cerqueira R; Lucchese AC; Magalhães E; Del Sant LC; Tuena MA; Nakahira C; Fava VAR; Steglich MS; Abdo GL; Barbosa MG; Sarin LM; Lacerda ALT
Clin Drug Investig; 2022 Oct; 42(10):865-873. PubMed ID: 36044154
[TBL] [Abstract][Full Text] [Related]
13. Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis.
Wang SM; Kim NY; Na HR; Lim HK; Woo YS; Pae CU; Bahk WM
Clin Psychopharmacol Neurosci; 2021 May; 19(2):341-354. PubMed ID: 33888663
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study).
Hong JP; Malek AZA; Li CT; Paik JW; Sulaiman AH; Madriaga G; Zhuo J; Siggins S; Fu DJ; Ju PC
Asia Pac Psychiatry; 2023 Dec; 15(4):e12548. PubMed ID: 37771084
[TBL] [Abstract][Full Text] [Related]
15. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Singh JB; Fedgchin M; Daly E; Xi L; Melman C; De Bruecker G; Tadic A; Sienaert P; Wiegand F; Manji H; Drevets WC; Van Nueten L
Biol Psychiatry; 2016 Sep; 80(6):424-431. PubMed ID: 26707087
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J
CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931
[TBL] [Abstract][Full Text] [Related]
17. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.
Zhou Y; Lan X; Wang C; Zhang F; Liu H; Fu L; Li W; Ye Y; Hu Z; Chao Z; Ning Y
J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):507-518. PubMed ID: 37414272
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
19. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial.
Wang S; Deng CM; Zeng Y; Chen XZ; Li AY; Feng SW; Xu LL; Chen L; Yuan HM; Hu H; Yang T; Han T; Zhang HY; Jiang M; Sun XY; Guo HN; Sessler DI; Wang DX
BMJ; 2024 Apr; 385():e078218. PubMed ID: 38808490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
